GlassScriptPhysician profile
Maximilian Oshalim
NPI 1407932015
$7,069.53
in general payments reported to CMS, 2019-2025
38 companies · $981 in 2025
The $981 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,408 · 2020: $580 · 2021: $1,031 · 2022: $991 · 2023: $359 · 2024: $720 · 2025: $981.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,059.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,059.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $2,144.90 | 2019-2025 | Biktarvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,186.10 | 2019-2024 | Xifaxan |
| Viiv Healthcare Company | $1,134.95 | 2019-2025 | Apretude, Cabenuva, Dovato |
| Merz North America, INC. | $399.27 | 2024-2025 | |
| Janssen Biotech, INC. | $278.74 | 2019-2022 | |
| Theratechnologies INC. | $196.43 | 2019 | |
| Merck Sharp & Dohme LLC | $165.93 | 2019-2025 | Pifeltro, Capvaxive |
| Lilly USA, LLC | $131.01 | 2024-2025 | Zepbound, Mounjaro |
| Napo Pharmaceuticals INC | $127.89 | 2019 | |
| Janssen Pharmaceuticals, INC | $123.72 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $89.25 | 2019-2021 | |
| Kaleo, INC. | $85.80 | 2019-2020 | |
| Exact Sciences Corporation | $68.82 | 2023-2024 | Cologuard Collection Kit |
| Abbvie INC. | $68.63 | 2019-2021 | |
| Antares Pharma, INC. | $64.93 | 2019-2025 | Xyosted |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $64.66 | 2019 | |
| Novo Nordisk INC | $64.35 | 2024-2025 | Wegovy |
| E.R. Squibb & Sons, L.L.C. | $55.66 | 2019 | |
| Pfizer INC. | $53.47 | 2019-2024 | |
| Eisai INC. | $52.75 | 2020-2021 | |
| Teva Pharmaceuticals USA, INC. | $52.44 | 2019-2020 | |
| Mylan Institutional INC. | $48.87 | 2019 | |
| Amarin Pharma, INC. | $43.81 | 2019-2021 | |
| Mylan Pharmaceuticals INC. | $41.77 | 2019 | |
| Aytu Biopharma, INC. | $33.46 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.52 | 2019 | |
| Clarus Therapeutics INC. | $32.11 | 2021 | |
| Neos Therapeutics, LP | $31.97 | 2019 | |
| Concordia Pharmaceuticals INC. | $31.46 | 2019 | |
| Medtronic, INC. | $27.51 | 2025 | Kyphon Express II Kyphopak Tray |
| Alk-Abello, INC | $23.46 | 2021 | |
| Bausch Health US, LLC | $21.33 | 2019 | |
| Adlon Therapeutics L.P. | $21.14 | 2021 | |
| Acerus Pharmaceuticals Corporation | $17.97 | 2021 | |
| Endo Pharmaceuticals INC. | $14.13 | 2019 | |
| Allergan, INC. | $13.67 | 2019 | |
| Sanofi Pasteur INC. | $13.64 | 2019 | |
| Phadia US INC. | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maximilian Oshalim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.